Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
| Autor: | Pedro Zitko, Jorge Chaverri, Ioannis Bakolis, Martin Hojman, Monica Thormann, Pablo Parenti, Sofía Sabato, Rosana Cuini, Rosa Teran, Jorge Contarelli, Carlos Beltrán, Wendy Moncada, Ana-Belen Arauz, Valeria Araujo, Miguel Morales, Liliana Calanni |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Latin Americans Anti-HIV Agents Population MEDLINE HIV Infections Infectious and parasitic diseases RC109-216 Zidovudine Health care medicine Humans education Tenofovir education.field_of_study business.industry Public health Lamivudine General Medicine Raltegravir Infectious Diseases Latin America Anti-Retroviral Agents business Demography medicine.drug |
| Zdroj: | International Journal of Infectious Diseases, Vol 113, Iss, Pp 288-296 (2021) |
| ISSN: | 1201-9712 |
| Popis: | Objective: To document antiretroviral use in Latin America during the last decade. Methods: We collected indicators from 79 HIV health care centres in 14 Latin American Spanish-speaking countries for 2013–2017. Indicators were analysed by age, sex and other characteristics and weighted by the estimated people under care (PUC) population in each country. Results: We gathered information on 116 299 PUC. One-third belonged to centres reporting a shortage of at least one antiretroviral therapy (ART) drug for >30 days during 2017. At end 2017, 95.1% of PUC were receiving ART. During 2013–2017, 45 329 people living with HIV were admitted to 39 centres. ART initiated during the first year after admission increased from 76.7% in 2013 to 83.8% in 2017. In 35 centres across the study period, 71.7% of PUC started ART with tenofovir disoproxil fumarate and lamivudine, and zidovudine use decreased. The third most common ART drug, EFV, reached 64.8%. Raltegravir and other alternatives increased annually to almost 10% of total use in 2017. Conclusions: Initial ART in Latin America is not based on the most recent scientific evidence and recommendations; use of drugs with higher efficacy and safety profiles and guarantee of ART availability continues to be a public health challenge. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|